Company / R&D per Share
Krystal Biotech, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.02
FY2025
5-year range
$1.26 / $2.02
FY2021-FY2025
Trend
+6.2%
vs FY2024
Sector context
#102 of 208
Health Care
What the data says
At $2.02, Krystal Biotech, Inc.'s r&d per share ranks #102 of 208 in the Health Care sector. R&D per Share has increased for 5 consecutive years, from $0.95 in FY2020 to $2.02 in FY2025.
Based on SEC 10-K filings.
2.02 in FY2025 with a 5-year CAGR of +16.1%.
Improved from $1.80 to $2.02 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +6.6%
- 5-Year CAGR
- +16.1%
- 10-Year CAGR
- -
Sector benchmark
#102 of 208 in Health CareTop 49% of 208This company $2.02 Sector average $28.82
▼
-93.0% below sector average
Key checks
Key Insights
- Krystal Biotech, Inc.'s r&d per share has grown for 5 consecutive years.
- In FY2025, r&d per share increased 6.2% year-over-year.
- Ranks #102 out of 208 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 5.66 (safe zone, above 2.9 threshold)
- Strong profit margin: 30.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.02 | +6.2% |
| FY2024 | $1.90 | +5.3% |
| FY2023 | $1.80 | +8.2% |
| FY2022 | $1.67 | +32.6% |
| FY2021 | $1.26 | +31.6% |
| FY2020 | $0.95 | -2.8% |
| FY2019 | $0.98 | +41.8% |
| FY2018 | $0.69 | +15.8% |
| FY2017 | $0.60 | -29.1% |
| FY2016 | $0.84 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026